Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis

Clinical Cancer Research

Volumn 5, Issue 12, 1999, Pages 3914-3919

  Diel, Ingo J ^a,c   Solomayer, Erich Franz ^a   Seibel, Markus J ^a   Pfeilschifter, Johannes ^a   Maisenbacher, Hartwig ^a   Gollan, Christina ^a   Pecherstorfer, Martin ^b   Conradi, Renate ^a   Kehr, Gudrun ^a   Boehm, Erwin ^a   Armbruster, Franz P ^a   Bastert, Gunther ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Wilhelminenspital ^*  (Austria)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; METHOTREXATE; PROGESTERONE RECEPTOR; SIALOPROTEIN; TAMOXIFEN;

ARTICLE; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 18544395211     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Galasko, C. S. B. Incidence and distribution of skeletal metastases. In: C. S. B. Galasko (ed.), Skeletal Metastases, pp. 14-21. London: Butterworth, 1986.
2. Rubens, R. D. The nature of metastatic bone disease. In: R. D. Rubens and I. Foglman (eds.), Bone Metastases. Diagnosis and Treatment, pp. 1-10. London: Springer, 1991.
3. Coleman, R. E., and Rubens, R. D. Bone metastases and breast cancer. Cancer Treat. Rev., 12: 251-270, 1985.
4. Coleman, R. E., and Rubens, R. D. The clinical course of bone metastases from breast cancer. Br. J. Cancer, 55: 61-66, 1987.
5. Coleman, R. E., Smith, P., and Rubens, R. D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br. J. Cancer, 77: 336-340, 1998.
6. Powell, G., Southby, J., Danks, J., et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res., 51: 3059-3061, 1991.
7. Bundred, N. J., Walker, R. A., Ratcliffe, W. A., Warwick, J., Morrison, J. M., and Ratcliffe, J. G. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur. J. Cancer, 28: 690-692, 1992.
8. Fisher, L. W., Whitson, W., Avioli, L. V., and Termine, J. D. Matrix sialoprotein of developing bone. J. Biol. Chem., 256: 12723-12727, 1983.
9. Fisher, L. W., McBride, O. W., Termine, J. D., and Young, M. F. Human bone sialoprotein. J. Biol. Chem., 265: 2347-2351, 1990.
10. Delmas, P. D., and Malaval, L. The proteins of bone. In: G. R. Mundy and T. J. Martin (eds.), Physiology and Pharmacology of Bone, pp. 673-724. Berlin: Springer, 1993.
11. Goldberg, H. A., Warner, K. J., Stillman, M. J., and Hunter, G. K. Determination of the hydroxyapatite-nucleating region of bone sialoprotein. Connect. Tissue Res., 35: 385-392, 1996.
12. Roach, H. I. Why does bone matrix contain non-collagenous proteins? The possible roles of osteocalcin, osteonectin, osteopontin and bone sialoprotein in bone mineralisation and resorption. Cell. Biol. Int., 18: 617-628, 1994.
13. Ross, F. P., Chappel, J., Alvarez, J. I., et al. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin αvβ3 potentiate bone resorption. J. Biol. Chem., 268: 9901-9907, 1993.
14. Bellahcène, A., Kroll, M., Liebens, F., and Castronovo, V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J. Bone Miner. Res., 11: 665-670, 1996.
15. Bellahcène, A., and Castronovo, V. Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. Bull. Cancer, 84: 17-24, 1997.
16. Karmatschek, M., Maier, I., Seibel, M. J., Woitge, H. W., Ziegler, R., and Armbruster, F. P. Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay. Clin. Chem., 43: 2076-2082, 1997.
17. Seibel, M. J., Woitge, H. W., Karmatschek, M., Armbruster, F. P., and Ziegler, R. A new radioimmunoassay for bone sialoprotein in serum, a potential marker of bone turnover. Clin. Lab., 42: 875-878, 1996.
18. Seibel, J. M., Woitge, H. W., Pecherstorfer, M., et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J. Clin. Endocrinol. Metab., 81: 3289-3294, 1996.
19. Withold, W., Armbruster, F. P., Karmatschek, M., and Reinauer, H. Bone sialoprotein in serum of patients with malignant bone diseases. Clin. Chem., 43: 85-91, 1997.
20. Bellahcène, A., Merville, M. P., and Castronovo, V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res., 54: 2823-2826, 1994.
21. Bellahcène, A., Menard, S., Bufalino, R., Moreau, L., and Castronovo, V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int. J. Cancer, 69: 350-353, 1996.
22. Fujisawa, R., Butler, W. T., Brunn, J. C., Zhou, H. Y., and Kuboki, Y. Differences in composition of cell-attachment sialoproteins between dentin and bone. J. Dent. Res., 72: 1222-1226, 1993.
23. Fujisawa, R., Nodasaka, Y., and Kuboki, Y. Further characterization of interaction between bone sialoprotein (BSP) and collagen. Calcif. Tissue Int., 56: 140-145, 1995.
24. Chenu, C., and Delmas, P. Platelets contribute to circulating levels of bone sialoprotein in human. J. Bone Miner. Res., 7: 47-54, 1992.
25. Bianco, P., Fisher, L. W., Young, M. F., Termine, J. D., and Robsy, P. G. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif. Tissue Int., 49: 421-426, 1991.
26. Bellahcène, A., Antolno, N., Clausse, N., et al. Detection of bone sialoprotein in human breast tissue and cell lines of both protein and messenger ribonucleic acid levels. Lab. Investig., 75: 203-210, 1996.
27. Chen, J., Shapiro, H., and Sadek, J. Developmental expression of bone sialoprotein mRNA in rat mineralized connective tissues. J. Bone Miner. Res., 7: 987-997, 1992.
28. Chen, J. McKee, M., Nanci, A., and Sadek, J. Bone sialoprotein mRNA expression and ultrastructural localization in fetal porcine calvarial bone: comparisons with osteopontin. Histochem. J., 26: 467-477, 1994.
29. Oldberg, A., Franzen, A., and Heinegard, D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc. Natl. Acad. Sci. USA, 83: 8819-8823, 1986.
30. Raynal, C., Delmas, P. D., and Chenu, C. Bone sialoprotein stimulates in vitro bone resorption. Endocrinology, 137: 2347-2354, 1996.
31. Stubbs, J. T. Generation and use of recombinant human bone sialoprotein and osteopontin for hydroxyapatite studies. Connect. Tissue Res., 35: 393-399, 1996.
32. Hunter, G., and Goldberg, H. Nucleation of hydroxyapatite by bone sialoprotein. Proc. Natl. Acad. Sci. USA, 90: 8562-8565, 1993.
33. Hunter, G. K., and Goldberg, H. A. Modulation of crystal formation by bone phosphoproteins: role of glutamic acid-rich sequences in the nucleation of hydroxyapatite by bone sialoprotein. Biochemistry, 302: 175-179, 1994.
34. Frappart, L., Boudeulle, M., Baumendil, J., et al. Structure and composition of microcalcifications in benign and malignant lesions of the breast. Hum. Pathol., 15: 880-889, 1984.
35. Mundy, G. R., Varani, J., Orr, W., Gondek, M. D., and Ward, P. A. Resorbing bone is chemotactic for monocytes. Nature (Lond.), 275: 132-136, 1978.
36. Orr, F. W., Varani, J., Gondek, M. D., Ward, P. A., and Mundy, G. R. Chemotactic response of tumor cells to products of resorbing bone. Science (Washington DC), 203: 176-179, 1979.
37. Miyauchi, A., Alvarez, J., Greenfield, E., et al. Recognition of osteopontin and related peptides by a αvβ3 integrin stimulates intermediate cell signals in osteoclasts. J. Biol. Chem., 266: 20369-20374, 1991.
38. Oldberg, A., Franzen, A., Heinegard, D., Pierschbacher, M., and Ruoslahti, E. Identification of a bone sialoprotein receptor in osteosarcoma cells. J. Biol. Chem., 263: 19433-19436, 1988.
39. van der Pluijm, G., Vloedgraven, H. J. M., Ivanov, B., et al. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res., 56: 1948-1955, 1996.
40. Yin, J. J., Spinks, T. J., Cui, Y., Dallas, M., and Guise, T. A. Clonal variation in parathyroid hormone-related protein (PTHrP) secretion by a human breast cancer cell line alters severity of osteolytic metastases. J. Bone Miner. Res., 12 (Suppl. 1): S107, 1997.
41. Guise, T. A., Yin, J. J., Taylor, S. D., et al. Evidence for a causal role of parathyroid hormone-related protein in breast cancer-mediated osteolysis. J. Clin. Investig., 98: 1544-1548, 1996.
42. Grill, V., Ho, P., Body, J. J., et al. Parathyroid related-protein: elevated levels in both humoral hypercalcemia and hypercalcemia complicating metastatic breast cancer. J. Clin. Endocrinol. Metab., 73: 1309-1315, 1991.
43. Diel, I. J., Solomayer, E. F., Costa, S. D., et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med., 339: 357-363, 1998.
44. Powles, T. J., Patterson, A. H. G., Nevantaus, A., et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proc. Am. Soc. Clin. Oncol., 17: 468, 1998.